XNAS
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2025-11-07 | Q3 2025 | -0.91 | -0.99 | -8.79% | $0 | ❌ Miss | — | — | — |
| 2025-08-08 | Q2 2025 | -0.93 | -0.86 | +7.53% | $0 | ✅ Beat | +0.56% | -2.14% | -11.67% |
| 2025-02-28 |
| Q4 2024 |
| -1.13 |
| -0.99 |
| +12.39% |
| $0 |
| ✅ Beat |
| -7.29% |
| -14.25% |
| -17.59% |
| 2024-11-08 | Q3 2024 | -0.90 | -1.05 | -16.67% | $0 | ❌ Miss | -4.09% | -18.46% | -9.67% |
| 2024-08-09 | Q2 2024 | -0.90 | -0.81 | +10.00% | $0 | ✅ Beat | -2.22% | +0.48% | +6.31% |
| 2024-05-10 | Q1 2024 | -0.95 | -0.90 | +5.26% | $0 | ✅ Beat | +4.94% | +1.37% | +17.00% |
| 2024-02-29 | Q4 2023 | -0.86 | -0.99 | -15.12% | $0 | ❌ Miss | — | — | — |
| 2023-11-13 | Q3 2023 | -0.68 | -0.71 | -4.41% | $0 | ❌ Miss | +5.00% | +17.39% | +43.24% |
Showing last 8 quarters.